# A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

> **NCT02431208** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 85 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02431208
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-22
- **Primary completion:** 2021-03-19
- **Final completion:** 2021-03-19
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2021-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431208, "A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02431208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*